![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
These patents disclose two classes of selective EP receptor ligands. That from Fujisawa claims a series of 4,5-biphenyloxazole derivatives that are indicated to be selective EP4 receptor antagonists. They are claimed to be useful in the treatment of glomerulonephritis. The application from Merck claims a series of 1,2-biphenylene derivatives, which are claimed to be EP (probably EP1) receptor antagonists useful in the treatment of pain and inflammatory diseases.